The collaboration explores innovative uses of data collected
Dublin, Ireland, 27 June 2018 – ICON plc, (NASDAQ: ICLR) a global provider of drug development services to the pharmaceutical, biotechnology and medical device industries, today announced that it is working with Practice Fusion to leverage active patient data in support of health research.
Practice Fusion, Inc., an Allscripts company, is an industry leading cloud-based ambulatory electronic health record (EHR) platform in the US, supporting more than 20,000 medical practices to deliver better care to over five million patients monthly. Practice Fusion offers connectivity solutions and services that can help make healthcare management better for everyone—including clinical labs, pharmacies, imaging centres, health systems and other US healthcare ecosystem stakeholders. These connected partners utilize the Practice Fusion platform to help coordinate care, and help develop innovative programs to improve outcomes, reduce costs and enhance the patient experience.
“The collaboration between ICON and Practice Fusion explores innovative uses of data collected directly through the Practice Fusion platform to facilitate health research. Focus areas for potential collaboration include: the ability to rapidly develop ‘Real-world’ Registries; the use of the EHR platform to streamline data collection for late phase studies and post-market research programs; as well as the real time identification of ‘active’ patients for engagement in health research programs”, commented Ramita Tandon, EVP ICON Commercialization and Outcomes.
Working with “Real” patient data, connected healthcare providers, and data collected directly through an EHR system represents an order of magnitude improvement over second-hand sources that the FDA has cited as filled with discrepancies and which is not timely.
The relationship with Practice Fusion is another example of ICON’s leadership in applying targeted technology to help customers reduce the time and cost of their development programs through more accurate patient identification, research though real-world patient records and faster patient recruitment.
“The use of EHR systems offers a significant differentiator of second-hand data resources for more efficient retrospective and hybrid studies in addition to selection of sites and patient recruitment” continued Ramita Tandon, EVP ICON Commercialization and Outcomes.
“Working with ICON will enable Practice Fusion network physicians to potentially improve the quality and value of patient care by accelerating research and actively contributing to Real-World Evidence which may be critical for developing novel treatments and communicating treatment value”, said Tom Langan, CEO, Payer & Life Sciences, Allscripts.
About ICON plc
ICON plc is a global provider of outsourced drug development and commercialisation services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specializes in the strategic development, management and analysis of programs that support clinical development from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 97 locations in 38 countries and has approximately 13,380 employees.
Further information is available at www.iconplc.com
ICON Media Contact
44-207 067 0557
This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.